Brazilian Pharmaceutical Industry Faces Patent Suspension Threat Amid U.S. Trade Tensions
核心洞察
Brazil is considering suspending pharmaceutical patents as retaliation against 50% U.S. tariffs, which could reduce medicine costs domestically but harm research and development investment.
The pharmaceutical industry warns that patent suspension could trigger negative effects beyond Brazil and the U.S., as patents remain crucial for innovation funding and corporate viability.
Legal experts caution that using compulsory licensing outside health emergencies could damage Brazil's regulatory predictability and international reputation as an intellectual property protector.
Brazil's pharmaceutical sector is confronting the possibility of patent suspensions as the government considers retaliatory measures against the United States' 50% tariffs on Brazilian exports. The proposal has sparked intense debate within the industry, with companies and legal experts warning of far-reaching consequences that could extend well beyond the immediate trade dispute.
Industry Opposition to Patent Suspension
Major pharmaceutical companies, including Pfizer, Novo Nordisk, Eli Lilly, Bayer, and EMS (搜索), have declined to comment directly on the potential measures, deferring to their industry associations' positions. Interfarma (搜索), Brazil's research-based pharmaceutical industry association, issued a strong statement emphasizing the critical role of patents in corporate performance and innovation incentives.
"Granting compulsory licenses or reducing patent terms could harm R&D investment and the economic viability of companies operating in Brazil," Interfarma (搜索) warned. The association stressed that any such action should remain "exceptional" as stated in the law and urged the government to "formally consult with patent holders before announcing any measures."
Novo Nordisk, currently battling to extend its semaglutide patent through Brazil's Superior Court of Justice, highlighted the substantial investments required for new drug development. "It is patent protection that enables the development of new medicines, which in turn are the foundation for future biosimilars and generics," the company stated in February.
Legal Framework and Precedents
The debate intensified following former U.S. President Donald Trump's tariff announcement, with Brazil's Ministry of Development, Industry, Trade and Services emphasizing that "any proposal for exceptional and provisional action" would be evaluated by the Interministerial Committee on Economic and Trade Negotiation and Countermeasures.
Attorney Ana Carolina Cagnoni noted that Brazil's Economic Reciprocity Law does not explicitly mention "patents" or compulsory licenses. Under Brazil's 1996 Intellectual Property Law, such measures are permitted only during public health emergencies, with compensation required for patent holders.
Brazil has limited precedent for patent suspension. The only significant case occurred in May 2007, when the federal government bypassed Merck (搜索)'s patent on Efavirenz for HIV (搜索) treatment. Brazil imported generic versions at $0.45 per pill, substantially lower than Merck's discounted offer of $1.11 after a 30% price reduction from $1.59.
Market Impact and Future Projections
A report from the Brazilian Fine Chemical Industry Association (Abifina) projects that more than 1,000 drugs will lose patent protection in Brazil over the next five years, representing a multibillion-real market shift. This natural patent cliff could significantly benefit Brazil's generics industry without requiring government intervention.
Fábio Couto, intellectual property partner at Veirano Advogados, acknowledged potential medium-term benefits for Brazil's generics sector and public healthcare costs. "There are high-cost medicines in the SUS [public health system] that could be mapped for potential domestic production. The generics sector could benefit—if it has the capacity," he said.
Legal and Regulatory Risks
However, both legal experts warn of significant risks associated with using patent suspension outside health emergencies. Cagnoni, founder of A2C Legal, stressed that such measures could erode Brazil's legal predictability. Couto agreed, noting that "this is a drastic measure via an uncommon route. The legal risk is high, and Brazil's regulatory environment could face intense pressure, both domestically and internationally—from investment decisions to its global image as a protector of IP rights."
Yi Shin Tang, professor of commercial law and international relations at the University of São Paulo, warned that if Brazil explicitly ties patent changes to retaliatory actions rather than invoking public interest or emergency grounds, the move could face legal challenges at the World Trade Organization.
Government Position and Process
Brazil's Ministry of Development, Industry, Trade and Services has indicated that any exceptional measures would undergo thorough evaluation. Article 5 of the relevant legislation mandates public consultations and the collection of suggestions on possible countermeasures, ensuring stakeholder input before implementation.
The trade dispute comes at a politically sensitive time for President Luiz Inácio Lula da Silva's administration, which faces sliding approval ratings and congressional friction while attempting to pass fiscal reforms. Despite these challenges, the trade tensions could paradoxically provide unintended political benefits by rallying domestic support around Brazilian sovereignty.